Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Chronic Plaque Psoriasis Market Size From 2025 to 2034?
The market size for chronic plaque psoriasis has seen robust growth over the past several years. It is projected to expand from a value of $20.79 billion in 2024 to $22.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.0%. Factors such as the increasing prevalence of psoriasis, a surge in co-morbidities, beneficial insurance reimbursement policies, raised levels of alcohol and tobacco use, along with the emergence of telemedicine, all contribute to the substantial growth observed in the historic period.
Anticipations of significant expansion are being made for the chronic plaque psoriasis market in the near future, with a projected growth to reach a hefty$29.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.9%. The expected growth during this forecast period can be tied to the increasing or decreasing occurrences of cpp globally, a rise in autoimmune diseases, an expansion in healthcare budgets, an aging demographic, and a growing demand for effective treatments. Key trends projected to emerge during this period comprise of progress in biologic treatments, the introduction of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the launch of biosimilars.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp
What are the Fundamental Drivers and Innovations Shaping the Chronic Plaque Psoriasis Market?
The escalation in instances of immune system dysregulation is predicted to boost the chronic plaque psoriasis market’s expansion. The term immune system dysregulation denotes a condition when the immune system doesn’t function optimally, resulting in a heightened vulnerability to infections, autoimmune diseases, and cancer. This increase in immune system dysfunctions is accredited to factors such as genetic factors, environmental influences, malnutrition, persistent stress, and the growing incidents of autoimmune diseases and infections like HIV. Treatment for chronic plaque psoriasis is necessary to control immune system dysfunctions as the immune system incorrectly instigates an excess production of skin cells, causing inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, an American nonprofit organization, disclosed that over 8 million Americans are plagued with psoriasis. On a global scale, this condition affects 125 million individuals, making up 2 to 3% of the total population. Hence, the escalating instances of immune system dysfunction are contributing to the growth of the chronic plaque psoriasis market.
How Is the Chronic Plaque Psoriasis Market Segmented?
The chronic plaque psoriasismarket covered in this report is segmented –
1) By Drug Class: Biologics; Small Molecule Drugs
2) By Route Of Administration: Injectable; Oral; Topical
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp
Which Regions Are Driving the Next Phase of the Chronic Plaque Psoriasis Market Growth?
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Chronic Plaque Psoriasis Market?
Leading companies within the chronic plaque psoriasis market are directing their efforts towards devising novel therapies, specifically IL-17A and IL-17F inhibitors, aiming at enhancing the treatment process for this condition. These suppressive biological treatments function by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines that play a significant role in immune responses, thereby mitigating inflammation associated with autoimmune disorders like chronic plaque psoriasis. An exemplar case of this occurred in October 2023 when UCB S.A., a biopharmaceutical corporation situated in Belgium, disclosed that BIMZELX (bimekizumab-bkzx) had received approval from the U.S. Food and Drug Administration (FDA). This authorization was for its use in treating adults suffering from moderate to extreme plaque psoriasis and who are suitable candidates for systemic therapy or phototherapy. Bimekizumab sets a new precedent as the premier psoriasis medication specifically created to inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both integral cytokines in inflammatory reactions. The FDA’s endorsement was grounded on data procured from three Phase 3 multicenter studies, labeled as BE READY, BE VIVID, and BE SURE. These trials undertook a comprehensive evaluation of its safety profile and efficacy among 1,480 patients diagnosed with moderate-to-severe plaque psoriasis.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report
How Is the Chronic Plaque Psoriasis Market Defined and What Are Its Core Parameters?
Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model